MANKIND PHARMA
Quarterly Results Analysis [Jun2025]
MANKIND PHARMA Quarterly Results
Consolidated | Jun2025 UnAudited |
Mar2025 UnAudited |
Dec2024 UnAudited |
Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹3,570 Cr | ₹3,079 Cr | ₹3,230 Cr | ₹3,077 Cr | ₹2,868 Cr | ₹2,422 Cr | ₹2,607 Cr | ₹2,708 Cr |
Expenses | ₹2,724 Cr | ₹2,396 Cr | ₹2,400 Cr | ₹2,226 Cr | ₹2,196 Cr | ₹1,836 Cr | ₹2,000 Cr | ₹2,025 Cr |
Operating Income | ₹847 Cr | ₹683 Cr | ₹830 Cr | ₹850 Cr | ₹672 Cr | ₹586 Cr | ₹607 Cr | ₹683 Cr |
Other Income | ₹80 Cr | ₹251 Cr | ₹77 Cr | ₹109 Cr | ₹99 Cr | ₹92 Cr | ₹70 Cr | ₹60 Cr |
Interest | ₹171 Cr | ₹191 Cr | ₹221 Cr | ₹7 Cr | ₹11 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr |
Depreciation | ₹219 Cr | ₹231 Cr | ₹192 Cr | ₹106 Cr | ₹103 Cr | ₹100 Cr | ₹110 Cr | ₹96 Cr |
Profit Before Tax | ₹537 Cr | ₹513 Cr | ₹494 Cr | ₹847 Cr | ₹657 Cr | ₹570 Cr | ₹558 Cr | ₹638 Cr |
Profit After Tax | ₹441 Cr | ₹427 Cr | ₹381 Cr | ₹656 Cr | ₹535 Cr | ₹475 Cr | ₹455 Cr | ₹508 Cr |
EPS | ₹10.62 | ₹10.20 | ₹9.22 | ₹16.31 | ₹13.39 | ₹11.76 | ₹11.33 | ₹12.51 |
Industry Peers & Returns | 1W | 1M | 1Y |
MANKIND PHARMA | -1.1% | 4% | 2.8% |
SUN PHARMACEUTICAL INDUSTRIES | 0.7% | -0.7% | -13.1% |
DIVIS LABORATORIES | 0.6% | -1.9% | 10.9% |
CIPLA | -0.1% | -0.3% | -6.1% |
TORRENT PHARMACEUTICALS | -1% | -3% | 2.3% |
DR REDDYS LABORATORIES | 0.6% | 3.7% | -1.6% |
ZYDUS LIFESCIENCES | -0.8% | 4.9% | -7.5% |
LUPIN | 2.1% | 3.1% | -9% |
AUROBINDO PHARMA | -1.2% | 0.6% | -30.3% |
MANKIND PHARMA Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 15.94 % |
Y-o-Y | 24.50 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Jun2025 | ₹3,570 Cr | 15.94 | |
Mar2025 | ₹3,079 Cr | -4.66 | |
Dec2024 | ₹3,230 Cr | 4.99 | |
Sep2024 | ₹3,077 Cr | 7.28 | |
Jun2024 | ₹2,868 Cr | 18.40 | |
Mar2024 | ₹2,422 Cr | -7.09 | |
Dec2023 | ₹2,607 Cr | -3.74 | |
Sep2023 | ₹2,708 Cr | - |
MANKIND PHARMA Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 23.94 % |
Y-o-Y | 26.09 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Jun2025 | ₹847 Cr | 23.94 | |
Mar2025 | ₹683 Cr | -17.67 | |
Dec2024 | ₹830 Cr | -2.38 | |
Sep2024 | ₹850 Cr | 26.58 | |
Jun2024 | ₹672 Cr | 14.54 | |
Mar2024 | ₹586 Cr | -3.33 | |
Dec2023 | ₹607 Cr | -11.16 | |
Sep2023 | ₹683 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 6.89 % |
Y-o-Y | 1.28 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Jun2025 | 23.72% | 6.89 | |
Mar2025 | 22.19% | -13.62 | |
Dec2024 | 25.69% | -7.02 | |
Sep2024 | 27.63% | 17.98 | |
Jun2024 | 23.42% | -3.22 | |
Mar2024 | 24.2% | 4.04 | |
Dec2023 | 23.26% | -7.74 | |
Sep2023 | 25.21% | - |
MANKIND PHARMA Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | 3.46 % |
Y-o-Y | -17.42 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Jun2025 | ₹441 Cr | 3.46 | |
Mar2025 | ₹427 Cr | 11.96 | |
Dec2024 | ₹381 Cr | -41.94 | |
Sep2024 | ₹656 Cr | 22.77 | |
Jun2024 | ₹535 Cr | 12.66 | |
Mar2024 | ₹475 Cr | 4.24 | |
Dec2023 | ₹455 Cr | -10.34 | |
Sep2023 | ₹508 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -10.82 % |
Y-o-Y | -33.69 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Jun2025 | 12.36 % | -10.82 | |
Mar2025 | 13.86 % | 17.46 | |
Dec2024 | 11.8 % | -44.68 | |
Sep2024 | 21.33 % | 14.43 | |
Jun2024 | 18.64 % | -4.85 | |
Mar2024 | 19.59 % | 12.20 | |
Dec2023 | 17.46 % | -6.88 | |
Sep2023 | 18.75 % | - |
MANKIND PHARMA Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 4.12 % |
Y-o-Y | -20.69 % |
Quarters | EPS | % Change | |
---|---|---|---|
Jun2025 | ₹10.62 | 4.12 | |
Mar2025 | ₹10.2 | 10.63 | |
Dec2024 | ₹9.22 | -43.47 | |
Sep2024 | ₹16.31 | 21.81 | |
Jun2024 | ₹13.39 | 13.86 | |
Mar2024 | ₹11.76 | 3.80 | |
Dec2023 | ₹11.33 | -9.43 | |
Sep2023 | ₹12.51 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs MANKIND PHARMA LTD